Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 13, 2011

Alkermes’ Vivitrol treats opioid dependence in study

Alkermes' Vivitrol (naltrexone for extended-release injectable suspension) has demonstrated sustained efficacy and safety over 18 months of treatment and supported its clinical ability as a treatment option for opioid dependence following opioid detoxification.

Alkermes’ Vivitrol (naltrexone for extended-release injectable suspension) has demonstrated sustained efficacy and safety over 18 months of treatment and supported its clinical ability as a treatment option for opioid dependence following opioid detoxification.

Vivitrol is a once-monthly, extended-release injectable medication, used to treat alcohol dependence and opioid dependence.

As measured by the number of opioid-free urine screens, Vivitrol, along with psychosocial treatment, reported prolonged efficacy and safety in a one-year, open-label extension of the six-month pivotal study.

The study also measured opioid craving, improvements in quality of life measures, self-reported opioid use and incidence of physical opioid dependence.

National Institute on Drug Abuse (NIDA) has awarded Small Business Innovation Research Program grant for the clinical development programme of Vivitrol.

 

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU